MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/01.inf.0000078156.03697.a5

Медицинская библиотека · The Pediatric infectious disease journal · 2003

Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.

Passwell Justen H, Ashkenazi Shai, Harlev Efrat, Miron Dan, Ramon Reut, Farzam Nahid, Lerner-Geva Liat, Levi Yonit, Chu Chiayung, Shiloach Joseph, Robbins John B, Schneerson Rachel, Israel Shigella Study Group

Клиническое исследованиеСтатьяРандомизированное исследованиеПоддержка службы здравоохранения СШАПеревод в очереди

Аннотация

BACKGROUND AND

OBJECTIVE

Shigella conjugate vaccines have been shown to be safe, immunogenic and efficacious in adult volunteers. We have now investigated the safety and immunogenicity of investigational Shigella sonnei and Shigella flexneri 2a conjugate vaccines in 1- to 4-year-old children, the age group at greatest risk for shigellosis.

METHODS

The O-specific polysaccharides of S. sonnei and S. flexneri 2a, the two most common shigellae from patients in Israel, were bound to medically useful carrier proteins to form conjugates. Eighty healthy 1- to 4-year-olds were randomized to receive two 0.5-ml im injections 6 weeks apart of either S. sonnei-CRM(9) or S. flexneri 2a-rEPA(succ). Blood was taken before, 6 weeks after the first injection, 4 weeks after the second injections and 2 years after immunization for assay of IgG anti-lipopolysaccharide, diphtheria toxin and Pseudomonas aeruginosa exotoxin A antibodies by enzyme-linked immunosorbent assay.

RESULTS

During an 8-day surveillance period after each immunization, low fever (37.8-39.0 degrees C) lasting only 24 to 48 h occurred in 2 of 40 recipients after the first injection and 4 of 40 recipients after the second injection of S. flexneri 2a-rEPA(succ) and in 2 of 38 of S. sonnei-CRM(9) after the second injection; no fever was detected after the first injection. Liver function tests were normal in all vaccinees. S. sonnei-CRM(9) elicited a >4-fold rise in IgG anti-LPS in 92.1% and S. flexneri 2a-rEPA(succ) in 85% (P < 0.0001) after the second injection; both conjugates elicited type-specific booster responses. At 2 years the geometric mean concentrations of both IgG anti-lipopolysaccharides were significantly higher than preimmunization levels. A >4-fold rise of IgG anti-diphtheria (65.8%) and IgG anti-ETA (77.5%) was observed.

CONCLUSION

These experimental Shigella conjugate vaccines were safe and immunogenic in 1- to 4-year-old children.

Для цитирования: Passwell Justen H, Ashkenazi Shai, Harlev Efrat, Miron Dan, Ramon Reut, Farzam Nahid, Lerner-Geva Liat, Levi Yonit, Chu Chiayung, Shiloach Joseph, Robbins John B, Schneerson Rachel, Israel Shigella Study Group. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.. The Pediatric infectious disease journal. 2003. DOI: 10.1097/01.inf.0000078156.03697.a5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.